Search academic texts

Information × Registration Number 0225U000910, (0122U000391) , R & D reports Title To develop the pharmacogenetic methods for preventing a decompensation heart failure in patients with coronary heart disease who have had COVID-19. popup.stage_title Розробити фармакогенетичні методи профілактики декомпенсації серцевої недостатності у хворих на ішемічну хворобу серця, які перенесли COVID-19. Head Rudyk Yurii S., д.мед.н. Registration Date 21-01-2025 Organization Government Institution "L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine" popup.description1 To develop different treatment regimens for heart failure decompensation prevention in patients with ischemic heart disease who suffered from coronavirus disease, taking into account clinical and pharmacogenetic aspects popup.description2  The study included patients with HF with ischemic heart disease. Of these 36.6 % patients had a history of COVID-19 with lung involvement, and 63.6 % without lung involvement. The patients to study the impact of the presence of LT3S, levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and polymorphisms of the β-adrenergic receptor system genes on the course of HF, taking into account the frequency of hospitalizations due to HF decompensation.. The frequency of recurrent hospitalizations of HF patients without lung involvement in COVID-19 was 20.6 %, while in patients with lung involvement – 45.3 % (χ2 = 24.505; p = 0.0001). There is a tendency to increase the frequency of recurrent hospitalizations in HF patients with established LT3S compared to those without this syndrome (31.7 % vs. 22.9 %, χ2 = 3.326; p = 0.068). It was found that the risk of LT3S increased in homozygous carriers of CC polymorphism at the Ser275 site of the G-protein β3 subunit gene: the odds ratio (OR) was 1.75 (95 % confidence interval (CI) 0.99–3.07; p = 0.054). The risk of increasing the concentration of TNF-α and IL-6 in HF patients was higher in homozygous carriers of CC polymorphism at the Ser275 site of the G-protein β3 subunit gene: OR = 4.55 (95 % CI 1.27–16.34); p = 0.028) and OR = 5.86 (95 % CI 1.81–19.00; p = 0.003). The risk of recurrent hospitalizations in HF patients with lung involvement in COVID-19 was associated with the heterozygous C/T polymorphism at the Ser275 site of the G-protein β3 subunit gene (OR = 4.36 (95 % CI 1.85–10.27; p = 0.022). Proinflammatory cytokines, influencing the conversion of T4 to T3, may contribute to the development of LT3 in patients with HF. There is an association between polymorphisms of the β-adrenergic receptor system genes, the risk of LT3 development, levels of proinflammatory cytokines, and recurrent hospitalizations in patients with HF who have had COVID-19 Product Description popup.authors Aleksieieva Maryna O. Babichev Denys P. Hasanov Yurii Ch. Kostiuk Olena I. Kravchenko Iryna H. Lozyk Tetiana V. Mazii Viktor V. Medentseva Olena O. Pyvovar Serhii M. Rudyk Yurii S. Samokhina Liubov M. Sydora Inna Ye. Strakhova Nataliia V. Udovychenko Maryna M. Usenko Maryna V. Chenchyk Tetiana O. Sheina Olha K. Shcheniavska Olena M. Shcherban Tetiana D. popup.nrat_date 2025-01-21 Close